Serum Cotinine and Adverse Cardiovascular Outcomes: A Cross-sectional Secondary Analysis of the nuMoM2b Heart Health Study
American Journal of Perinatology · 01.09.2023 · 40 (12) · 1311-1320
DOI: 10.1055/a-1580-3155 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift American Journal of Perinatology, erschienen am 01.09.2023. Verfasst von Lauren H Theilen und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, School of Medicine, University of Utah, Salt Lake City, Utah. Hauptthemen laut MEDLINE: Cotinine, Tobacco Smoke Pollution, Cardiovascular Diseases, Pregnancy Complications. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NCATS NIH HHS, NICHD NIH HHS.
Abstract (Originalsprache)
Objective
We aimed to (1) compare serum cotinine with self-report for ascertaining smoking status among reproductive-aged women; (2) estimate the relative odds of adverse cardiovascular (CV) outcomes among women by smoking status; (3) assess whether the association between adverse pregnancy outcomes (APOs) and CV outcomes varies by smoking status. Study Design We conducted a cross-sectional study of the nuMoM2b Heart Health Study. Women attended a study visit 2 to 7 years after their first pregnancy. The exposure was smoking status, determined by self-report and by serum cotinine. Outcomes included incident chronic hypertension (HTN), metabolic syndrome (MetS), and dyslipidemia. Multivariable logistic regression estimated odds ratios (ORs) for each outcome by smoking status.
Results
Of 4,392 women with serum cotinine measured, 3,610 were categorized as nonsmokers, 62 as secondhand smoke exposure, and 720 as smokers. Of 3,144 women who denied tobacco smoke exposure, serum cotinine was consistent with secondhand smoke exposure in 48 (1.5%) and current smoking in 131 (4.2%) After adjustment for APOs, smoking defined by serum cotinine was associated with MetS (adjusted OR [aOR] = 1.52, 95% confidence interval [CI]: 1.21, 1.91) and dyslipidemia (aOR = 1.28, 95% CI: 1.01, 1.62). When stratified by nicotine exposure, nonsmokers with an APO in their index pregnancy had higher odds of stage 1 (aOR = 1.64, 95% CI: 1.32, 2.03) and stage 2 HTN (aOR = 2.92, 95% CI: 2.17, 3.93), MetS (aOR = 1.76, 95% CI: 1.42, 2.18), and dyslipidemia (aOR = 1.55, 95% CI: 1.25, 1.91) relative to women with no APO. Results were similar when smoking exposure was defined by self-report.
Conclusion
Whether determined by serum cotinine or self-report, smoking is associated with subsequent CV outcomes in reproductive-aged women. APOs are also independently associated with CV outcomes in women. Key Points
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, School of Medicine, University of Utah, Salt Lake City, Utah.
- Division of Biostatistics and Epidemiology, RTI International, Research Triangle Park, North Carolina.
- Division of Biostatistics, RTI International, Research Triangle Park, North Carolina.
- Department of Obstetrics and Gynecology, Northwestern University, Chicago, Illinois.
- Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburg, Pittsburg, Pennsylvania.
- Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute (NHLB), Bethesda, Maryland.
Förderung
- NHLBI NIH HHS
- NCATS NIH HHS
- NICHD NIH HHS
- National Heart, Lung, and Blood Institute
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- National Institutes of Health
Zitieren
APA
Theilen, L. H., McNeil, R. B., Hunter, S., Grobman, W. A., Parker, C. B., Catov, J. M., Pemberton, V. L., Ehrenthal, D. B., Haas, D. M., Hoffman, M. K., Chung, J. H., Mukhtar, F., Arzumanyan, Z., Mercer, B., Parry, S., Saade, G. R., Simhan, H. N., Wapner, R. J., Silver, R. M., & NHLBI nuMoM2b Heart Health Study Network (2023). Serum Cotinine and Adverse Cardiovascular Outcomes: A Cross-sectional Secondary Analysis of the nuMoM2b Heart Health Study. American Journal of Perinatology, 40(12), 1311-1320. https://doi.org/10.1055/a-1580-3155
Vancouver
Theilen LH, McNeil RB, Hunter S, Grobman WA, Parker CB, Catov JM, et al. Serum Cotinine and Adverse Cardiovascular Outcomes: A Cross-sectional Secondary Analysis of the nuMoM2b Heart Health Study. American Journal of Perinatology. 2023;40(12):1311-1320. doi:10.1055/a-1580-3155
BibTeX
@article{Theilen2023,
author = {Theilen, Lauren H and McNeil, Rebecca B and Hunter, Shannon and Grobman, William A and Parker, Corette B and Catov, Janet M and Pemberton, Victoria L and Ehrenthal, Deborah B and Haas, David M and Hoffman, Matthew K and Chung, Judith H and Mukhtar, Farhana and Arzumanyan, Zorayr and Mercer, Brian and Parry, Samuel and Saade, George R and Simhan, Hyagriv N and Wapner, Ronald J and Silver, Robert M and NHLBI nuMoM2b Heart Health Study Network, NHLBI nuMoM2b Heart Health Study Network},
title = {Serum Cotinine and Adverse Cardiovascular Outcomes: A Cross-sectional Secondary Analysis of the nuMoM2b Heart Health Study},
journal = {American Journal of Perinatology},
year = {2023},
volume = {40},
number = {12},
pages = {1311--1320},
doi = {10.1055/a-1580-3155}
}
EUVIMED